Bench to Bedside and Beyond
Stories from Fred Hutch Cancer Center about how our scientists and clinicians are combining innovative research with compassionate care to address the impact of cancer and infectious disease. You'll hear from patients, researchers, doctors, caregivers, supporters and others seeking to prevent and eliminate cancer.
info_outline
Sherlock Holmes in a lab coat solves two molecular mysteries at Fred Hutch
10/14/2026
Sherlock Holmes in a lab coat solves two molecular mysteries at Fred Hutch
Dr. Jeremy Hollis talks with John Higgins about the two molecular mysteries that he solved on the way to earning his doctorate degree at Fred Hutch Cancer Center. His solution to the first case provided insight into the evolution of the human immune system and opened new possibilities for drugs and therapies when cell signaling goes awry. His solution to the second showed researchers a new way to trace the evolution of life’s most ancient molecular machines when genomic sequences become unrecognizable using standard methods. Takeaways: In just six years in the Basic Sciences Division, Jeremy Hollis recruited the help of colleagues in four Fred Hutch labs and published the results of both investigations in two scientific journals, even before anyone could officially call him Dr. Hollis. Solving the case of the Wonky Antenna for his doctoral thesis, Dr, Jeremy Hollis provided insight into the evolution of the human immune system and opened new possibilities for drugs and therapies when cell signaling goes awry. Solving the Case of the Vanishing Chaperone, Dr, Jeremy Hollis showed researchers a new way to trace the evolution of life’s most ancient molecular machines when genomic sequences become unrecognizable using standard methods.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/43297544
info_outline
What you need to know about hereditary cancer risk with Dr. Rachel Yung
09/28/2026
What you need to know about hereditary cancer risk with Dr. Rachel Yung
In this episode of Bench to Bedside and Beyond, Fred Hutch’s Diane Mapes talks with clinical researcher and breast cancer oncologist Dr. Rachel Yung, co-director of the Breast and Ovarian Cancer Prevention Clinic at Fred Hutch, about hereditary cancer risk, genetic testing for hereditary cancers and ways to reduce your risk if you are told you have a pathogenic variant. Key takeaways: Inherited cancers seen most often include breast, prostate and colorectal cancers. How BRCA1 and BRCA2-related risks compare with other genetic variants such as ATM and CHEK2. What happens after genetic testing, from counseling to specialized prevention and surveillance care. Options for reducing risk: earlier screening, imaging, medication, lifestyle changes and preventive surgery when appropriate. How a genetic variant can raise risk but does not guarantee cancer. How fertility, menopause and personal circumstances factor into prevention decisions. The difference between clinical genetic testing and direct-to-consumer results. What a variant of unknown significance means—and why people generally should not make medical decisions based on it alone. The overall takeaway is that genetic information can help people make informed, individualized choices with support from qualified clinicians and counselors.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/43063393
info_outline
In the Lab with Dr. Matthew Ross: making hand-held science with a 3D printer
09/25/2026
In the Lab with Dr. Matthew Ross: making hand-held science with a 3D printer
Dr. Matthew Ross talks with John Higgins about the problems he has solved for Fred Hutch researchers using a donated 3D printer. Ross, the communications liaison for Fred Hutch Cancer Center’s Basic Sciences Division, used the printer to fabricate small parts, make customized tools and create scale models of life’s smallest molecular machines. Scientists and aspiring scientists can hold these models in their hands to see — and feel — their shape to infer their function. Key takeaways Dr. Matthew Ross uses a donated 3D printer to make spare parts, customized tools and models of life’s smallest molecular machines for teaching and learning. 3D printing helps the Basic Sciences Division maintain older, specialized equipment, saving money that can be reinvested in research. Scale models of proteins that researchers can hold in their hands provide tangible information about their structure, making the visual science of structural biology more accessible to someone with visual impairments.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/43034713
info_outline
A More Precise Way to Understand Tubo-Ovarian Cancer
09/14/2026
A More Precise Way to Understand Tubo-Ovarian Cancer
In this episode of Bench to Bedside and Beyond, Diane Mapes talks with Fred Hutch Cancer Center and UW Medicine clinical researcher and gynecologic oncologist Dr. Elizabeth Swisher about research that may refine how scientists understand and treat tubo-ovarian cancer — and potentially help guide targeted treatment for some people with triple-negative breast cancer. Swisher explains why many cancers long called ovarian cancer begin in the fallopian tubes, why “tubo-ovarian cancer” is a more accurate term and how researchers are studying tumors’ current biological vulnerabilities to better match patients with treatment options. The conversation also explores HRDefine, an investigational assay designed to identify the current causes of homologous recombination deficiency, or HRD, a tumor weakness that can make some cancers responsive to PARP inhibitors. Key takeaways Many cancers commonly called ovarian cancer begin in the fallopian tubes. Using the term tubo-ovarian cancer more accurately reflects where these cancers often originate and may inform future prevention and early-detection research. Homologous recombination deficiency, or HRD, is a weakness in how some tumor cells repair damaged DNA. That weakness can make certain tumors more responsive to PARP inhibitors. Swisher and colleagues developed HRDefine, an investigational assay designed to identify the current cause of HRD. It can examine BRCA1/2 and other gene changes, as well as methylation changes that can affect gene activity. Unlike older measures of HRD, which may continue to show a past vulnerability after a tumor has become resistant to treatment, HRDefine is designed to assess the tumor’s current biology. The assay may help identify which patients are most likely to benefit from PARP inhibitors in tubo-ovarian cancer and, potentially, triple-negative breast cancer. It is still being validated in hundreds of samples before any broader clinical or commercial use. This work reflects a broader goal of precision oncology: matching treatment decisions to a tumor’s biological features, not solely to the organ where the cancer began or to inherited genetic risk.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/42900465
info_outline
Living with the long-term effects of prostate cancer, from sexual to spiritual
09/02/2026
Living with the long-term effects of prostate cancer, from sexual to spiritual
In this episode of Bench to Bedside and Beyond, we talk to a 25-year prostate cancer survivor and the director of the new sexual health clinic at Fred Hutch about why it’s important to include sexual health in the survivorship conversation. Prostate cancer survivor James DeLong and Kelly Nelson, director of Fred Hutch’s new sexual health clinic, discuss how a cancer diagnosis can wreak havoc on a person’s sex life—and how people no longer need to suffer in silence. Key takeaways: The side effects of cancer treatment can make having a healthy sex life challenging. For a long time, providers didn’t commonly address issues such as low libido, vaginal dryness and painful intercourse. Many patients were embarrassed to bring it up, and providers didn’t ask. Fred Hutch’s new sexual health clinic was created to address these topics and normalize the conversation, recognizing that sexual health is an important part of survivorship and quality of life. The clinic provides comprehensive, individualized support including medication, sex therapy and pelvic-floor physical therapy.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/42717705
info_outline
In the Lab with Dr. Rashmi Mishra: Shapeshifting cancer into a more treatable form
08/21/2026
In the Lab with Dr. Rashmi Mishra: Shapeshifting cancer into a more treatable form
John Higgins interviews Dr. Rashmi Mishra, a postdoctoral research fellow in the Hsieh Lab at Fred Hutch Cancer Center, about how aggressive prostate cancer shapeshifts from a form that is treatable with drugs to a more lethal form that is much less treatable. In a recent study, she and her colleagues found potential ways to reverse that trick, forcing tumor cells to shapeshift back into the more treatable form. Their discovery opens a new line of attack against aggressive prostate cancer, as well as breast cancer and possibly other cancers. Key Takeaways: Prostate cancer comprises two main types of cells: luminal, which is more treatable with existing therapies and a more aggressive, lethal type called basal, which is much less treatable. A recent study by Dr. Rashmi Mishra, a postdoctoral research fellow in the Hsieh Lab at Fred Hutch Cancer Center, describes how prostate cancer shapeshifts from a luminal to a basal form to elude therapy without reprogramming its DNA. Mishra and her colleagues found potential ways to reverse that shapeshifting trick, forcing tumor cells to shapeshift back into the more treatable form. Their discovery opens a new line of attack against aggressive prostate cancer, as well as breast cancer and possibly other cancers.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/42494205
info_outline
After cancer treatment, emotional and spiritual health is key to maintaining equilibrium
08/14/2026
After cancer treatment, emotional and spiritual health is key to maintaining equilibrium
In this episode of Bench to Bedside and Beyond, Bonnie Rochman talks to a bone marrow transplant survivor and the director of psychiatry at Fred Hutch. Leukemia survivor and bone marrow transplant recipient Nicole Sandburg and Jesse Fann, MD, MPH, Medical Director, Psychiatry and Psychology, discuss the ways a cancer diagnosis can upend emotional health and how mental health services including mindfulness can help patients cope. Key takeaways: Dealing with cancer can have profound emotional effects that outlast the treatment. Recovery requires more than physical healing. Cancer strengthens a person’s self-advocacy skills. People dealing with cancer can help support their emotional well-being by staying active, eating healthy, socializing and getting outdoors.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/42422780
info_outline
In the Lab with Dr. Lucas Sullivan: let cancer eat cake
08/13/2026
In the Lab with Dr. Lucas Sullivan: let cancer eat cake
Dr. Lucas Sullivan, a cancer metabolism expert at Fred Hutch Cancer Center talks with John Higgins about a new study showing that cancers driven by a specific mutation crave a nutrient so much that eating too much of it can be lethal. Healthy cells aren’t prone to stuffing themselves with this nutrient. That difference presents an opportunity for precision oncology: we can supplement a patient’s diet to force-feed tumors the nutrient while sparing healthy cells. Key takeaways: A recent study by Dr. Lucas Sullivan, a cancer metabolism expert, finds that feeding NRF2-mutated tumors too much of a nutrient they crave makes them vulnerable to slower growth and cell death. NRF2 genetic mutations are common in lung cancers but also appear in several other cancers. Force-feeding NRF2-mutated tumors the nutrient they crave could kill the cancerous cells while sparing the healthy ones, a prime example of precision oncology.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/42422025
info_outline
Sidelining cancer treatment's side effects through exercise, nutrition, prehab and rehab
07/15/2026
Sidelining cancer treatment's side effects through exercise, nutrition, prehab and rehab
Cancer survivorship is about far more than finishing treatment. In this episode of Bench to Bedside and Beyond, Diane Mapes speaks with prostate cancer survivor and advocate Marty Chakoian and cancer rehabilitation specialist Dr. Hanna Hunter about the physical, emotional and practical realities of life after a cancer diagnosis. Together, they discuss treatment side effects, the value of patient advocacy and support groups, advances in less toxic therapies, and how rehabilitation, exercise and supportive care services help patients maintain quality of life throughout the cancer continuum. Key Takeaways Cancer care is increasingly focused on quality of life, not just survival. Modern oncology aims to treat the whole person, balancing effective cancer treatment with physical function, emotional well-being, independence and long-term survivorship outcomes. Both Chakoian and Hunter emphasize that living well during and after treatment is now a core goal of cancer care. Patients play a critical role in treatment decisions. Chakoian stresses the importance of shared decision-making, encouraging patients to understand their diagnosis, know their personal values and communicate openly with their care teams. The best treatment plan is often the one that balances medical effectiveness with the quality-of-life outcomes that matter most to the individual patient. Supportive care and rehabilitation can start before treatment begins. Dr. Hunter explains that rehabilitation services including physical therapy, lymphedema care, speech therapy and exercise programs can help patients before, during and after treatment. Early intervention can improve resilience, reduce side effects and help patients recover more quickly. Exercise and community support are powerful survivorship tools. Research increasingly shows that physical activity can improve function, quality of life and even cancer outcomes. At the same time, support groups provide practical advice, emotional support and a sense of community that helps people navigate the challenges of cancer and its aftermath.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/42105260
info_outline
Beyond the Five-Year Myth: How Survivorship Care Helps Cancer Patients Live Well
06/24/2026
Beyond the Five-Year Myth: How Survivorship Care Helps Cancer Patients Live Well
In this episode of From Bench to Bedside and Beyond, host Diane Mapes talks with Dr. Vidhya Nair, medical director of adult cancer survivorship at Fred Hutch, about what truly happens after active cancer treatment ends. Together, they explore late and long-term side effects, fear of recurrence, and the emotional whiplash many patients feel when treatment stops but symptoms and worries do not. Dr. Nair also explains how Fred Hutch’s evolving survivorship program—from embedded care in disease clinics to specialized services in rehab, sexual health, and integrative medicine—helps survivors navigate life after cancer with more support and less uncertainty. Survivorship is more than “being done” with treatment; it is a structured phase of care focused on late and long-term effects, surveillance for recurrence, and helping patients move forward informed rather than fearful. Fred Hutch is embedding survivorship into disease-specific clinics and expanding specialized services such as cancer rehabilitation, sexual health, integrative medicine, and psychosocial support so more patients receive tailored help over 5–10 years after treatment. Survivorship care plans and primary care collaboration give survivors clear guidance on symptoms to watch for, risks like secondary cancers and osteoporosis, and practical steps—exercise, nutrition, and mental health support—to live as well as possible after cancer.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/41783150
info_outline
From Treatment to Thriving: Redefining Cancer Survivorship
06/04/2026
From Treatment to Thriving: Redefining Cancer Survivorship
As cancer survival rates rise, “survivorship” has emerged as a critical new phase of care - one that extends far beyond treatment and into long-term physical, emotional, and psychological recovery. Through firsthand stories from a breast cancer survivor and a melanoma survivor-turned-provider, this episode reveals how patients navigate side effects, fear of recurrence, and life-altering changes that can last for decades. It also highlights how survivorship programs at Fred Hutch are evolving to support patients earlier and more holistically, helping them move from treatment toward living well. Key takeaways Survivorship starts at diagnosis, not after treatment ends—and often means coping with the effects of treatment, not just the cancer itself. Cancer care leaves lasting impacts across physical health, mental health, relationships, and finances, requiring ongoing support long after therapy. New treatments like immunotherapy are transforming outcomes, but their long-term effects are still being understood. Modern survivorship programs are expanding earlier and more holistically, meeting patients where they are and helping them rebuild strength, confidence, and quality of life.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/41543065
info_outline
How Wildfire Smoke, Light at Night, and 'Solar Jet Lag' Can Increase Cancer Risk
04/06/2026
How Wildfire Smoke, Light at Night, and 'Solar Jet Lag' Can Increase Cancer Risk
In this episode, Trang VoPham, PhD, MPH, MS, from Fred Hutch Cancer Center discusses the impact of environmental exposures like wildfire smoke and solar jet lag on health with Diane Mapes from Fred Hutch News. Dr. VoPham also lists other potential risks, such as for liver cancer, and offers potential strategies for mitigation of these impacts. One takeaway: Where you live in a time zone impacts your circadian rhythms and your risks for disease.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/40747045
info_outline
Why do we choose the ‘quick fix’ over tried-and-true cancer prevention?
03/03/2026
Why do we choose the ‘quick fix’ over tried-and-true cancer prevention?
In this episode of From Bench to Bedside and Beyond, Fred Hutch psychologist and public health researcher Dr. Jonathan Bricker, who holds the Endowed Chair in Cancer Prevention, talks to Diane Mapes about why people embrace dietary supplements, which are unregulated by the FDA and require no safety or scientific studies, and turn away from science-based cancer prevention like the HPV vaccine. “It’s not about ignorance or misinformation,” Bricker said. “It’s about a basic human desire to avoid discomfort and to have control.” Takeaways: Many people take supplements in order to improve health and avoid cancer. But large clinical trials led by Fred Hutch have found some supplements actually promote, not prevent, cancer. At the same time, vaccine hesitancy is increasing – even for safe, long-studied vaccines that actually prevent cancer. What’s the psychology behind our willingness to embrace ‘quick fixes’ like supplements and peptides even when there’s little science behind their efficacy, and turn away from tried-and-true cancer prevention like the HPV vaccine? It’s about a ‘basic human desire to avoid discomfort and to have control,’ Bricker said. Dietary supplements ‘aren’t just biological interventions, they’re psychological interventions,’ Bricker said, because they promise immediate action and give us agency. Public health messaging tends to take a rational approach. This triggers fear, which then drives people toward the ‘quick biomedical fix.’ It creates a “psychological feedback loop.”
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/40302710
info_outline
From diagnosis to biking in Croatia: a kidney cancer patient’s journey
03/03/2026
From diagnosis to biking in Croatia: a kidney cancer patient’s journey
In this episode of From Bench to Bedside and Beyond, Dr. Yaw Nyame and patient Dave Lucas talk with Fred Hutch's Bonnie Rochman on exploring innovative kidney cancer treatments, robotic surgery and the importance of personalized care. Discover how advanced surgical techniques and patient-centered approaches can lead to remarkable recovery stories like Lucas's. Takeaways Robotic surgery can significantly reduce recovery time for complex cases Personalized care involves understanding patient goals and lifestyle. Advanced surgical techniques require meticulous planning and teamwork.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/40302270
info_outline
Cancer patient advocate reinforces importance of normalizing conversations about symptoms
12/15/2025
Cancer patient advocate reinforces importance of normalizing conversations about symptoms
In this conversation, Margie Wilson talks to Fred Hutch Cancer Center’s Bonnie Rochman about her experience being diagnosed with endometrial cancer and her evolution into a patient advocate for Black women. She discusses her initial symptoms and treatment, the challenges of navigating the medical system, and the importance of having open conversations about women's health and finding a supportive healthcare provider. Margie was diagnosed with endometrial cancer in 2016 after experiencing unexplained bleeding that she attributed to menopause. The first oncologist she saw was dismissive and rushed, but finding a compassionate and understanding doctor made a significant difference in her treatment experience. Brachytherapy was a key part of her treatment plan. Margie became involved with ECANA to advocate for Black women with endometrial cancer. Education and awareness are vital in saving lives and improving health outcomes for women.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/39418540
info_outline
CAR T-cell therapy with Dr. Mazyar Shadman
11/25/2025
CAR T-cell therapy with Dr. Mazyar Shadman
Dr. Mazyar Shadman is a blood cancer specialist at Fred Hutch Cancer Center who focuses on lymphoid malignancies. In a conversation with Bonnie Rochman, they explore the advancements in CAR T-cell therapy, particularly for large B-cell lymphoma, highlighting its impact on patient outcomes and survival rates. Takeaways CAR T therapy is a significant advancement in cancer treatment. The future of cancer treatment may heavily rely on CAR T advancements. CAR T therapy represents a shift in cancer care paradigms. It is particularly effective for large B-cell lymphoma. Patients with relapsed disease historically had limited survival chances. CAR T therapy has improved outcomes for high-risk patients. 30 to 40% of patients are now being cured with CAR T therapy. The treatment offers better quality of life compared to standard care. Ongoing research is crucial for further advancements in CAR T. Patient selection is key for the success of CAR T therapy.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/39169815
info_outline
Delivering the Best Possible Cancer Care with Tom Purcell
11/05/2025
Delivering the Best Possible Cancer Care with Tom Purcell
In this conversation, Dr. Tom Purcell, Chief Medical Officer at Fred Hutch Cancer Center, discusses his role in overseeing quality care delivery and patient satisfaction with Bonnie Rochman. He reflects on his previous experience in a community cancer program and emphasizes the importance of a multidisciplinary team approach in optimizing patient care. The conversation also touches on the cultural shifts necessary for improving healthcare delivery and the ongoing efforts to enhance patient access and satisfaction.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/38926480
info_outline
Frogs help Fred Hutch find the shape of small things
10/27/2025
Frogs help Fred Hutch find the shape of small things
Frogs are back at Fred Hutch after a long absence to study the structure of DNA-linked molecular complexes that change during the cell cycle and malfunction in cancer and other diseases. Fred Hutch writer / editor John Higgins discusses his latest story on the current and past frog research with multimedia editor Robert Hood.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/38799730
info_outline
The Message Is the Medium - David Patton and Robert Hood
10/22/2025
The Message Is the Medium - David Patton and Robert Hood
After more than a decade of providing high-quality cancer and research stories via the Fred Hutch website, the organization is evolving its storytelling to go beyond the browser. David Patton, Fred Hutch's content strategy lead, talks with Heart of the Hutch producer and multimedia editor Robert Hood about this dynamic storytelling evolution. The goal is to reach audiences with the same high value cancer and science information in the platforms and formats they are now relying on more often. Learn more at FredHutch.com/News
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/38733615
info_outline
When work becomes personal - John Scheleen
09/24/2025
When work becomes personal - John Scheleen
Welcome to Bench to Bedside and Beyond, stories from Fred Hutch Cancer Center about how our scientists and clinicians are combining innovative research with compassionate care to address the impact of cancer and infectious disease. You'll hear from patients, researchers, doctors, caregivers, supporters and others seeking to prevent and eliminate cancer. In this conversation, John Scheleen talks about his experience being treated for cancer for much of his tenure as a Fred Hutch employee with Bonnie Rochman, a writer for Fred Hutch News. Scheleen recounts how he found a "weird mole" that catapulted him out of the world of grants and financial reports and into the world of patient care. He recalls what it was like to wait for biopsy results during the weekend in which his son celebrated his first birthday, a time of anxiety and joy. And he explains that his work closing out grants is especially meaningful when he recognizes the names of providers who have treated him.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/38346190
info_outline
Gratitude inspires a job search - Tiffany Bucklin
09/24/2025
Gratitude inspires a job search - Tiffany Bucklin
Welcome to Bench to Bedside and Beyond, stories from Fred Hutch Cancer Center about how our scientists and clinicians are combining innovative research with compassionate care to address the impact of cancer and infectious disease. You'll hear from patients, researchers, doctors, caregivers, supporters and others seeking to prevent and eliminate cancer. In this conversation, Tiffany Bucklin talks about her unwavering commitment to getting a job at Fred Hutch after her husband was treated here for leukemia. She tells Bonnie Rochman, a writer for Fred Hutch News, how her husband's care team impressed her by remembering their children's names. Bucklin reflects on how it felt to have the team take a "vested interest in our story and how it ended."
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/38346090
info_outline
From guinea pig to long-term survivor - Chris Lundy
09/24/2025
From guinea pig to long-term survivor - Chris Lundy
Welcome to Bench to Bedside and Beyond, stories from Fred Hutch Cancer Center about how our scientists and clinicians are combining innovative research with compassionate care to address the impact of cancer and infectious disease. You'll hear from patients, researchers, doctors, caregivers, supporters and others seeking to prevent and eliminate cancer. In this conversation, Chris Lundy tells Bonnie Rochman, a writer for Fred Hutch News, what it was like to be among the first wave of bone marrow transplant recipients. Lundy was 21 and in the military when he came to Fred Hutch in 1971 for a life-saving transplant. He recalls being told that he had a 10% chance of survival. More than 50 years later, he reflects on how he beat the odds in a big way.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/38345890
info_outline
A mother-daughter connection - Bonnie and Katie Kraskouskas
09/23/2025
A mother-daughter connection - Bonnie and Katie Kraskouskas
Welcome to Bench to Bedside and Beyond, stories from Fred Hutch Cancer Center about how our scientists and clinicians are combining innovative research with compassionate care to address the impact of cancer and infectious disease. You'll hear from patients, researchers, doctors, caregivers, supporters and others seeking to prevent and eliminate cancer. In this conversation, Bonnie Kraskouskas shares her pride with Bonnie Rochman, a writer for Fred Hutch News, at having her daughter, Katie, work in research at Fred Hutch—two decades after she first enrolled baby Katie at Hutch Kids daycare. Bonnie talks about what it's like to retire after more than 30 years at Fred Hutch managing grants, knowing that her daughter is continuing to contribute to Fred Hutch's mission. Katie reflects on the impact that her high school biology teacher, who participated in Fred Hutch's Science Education Partnership program, had on her future career. In a full-circle moment, Katie notes she now works at the same desk where she observed the operations of her lab as a high schooler.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/38287270
info_outline
Being a bone marrow donor for a brother - Jenn Vehrs
09/03/2025
Being a bone marrow donor for a brother - Jenn Vehrs
Welcome to Bench to Bedside and Beyond, stories from Fred Hutch Cancer Center about how our scientists and clinicians are combining innovative research with compassionate care to address the impact of cancer and infectious disease. You'll hear from patients, researchers, doctors, caregivers, supporters and others seeking to prevent and eliminate cancer. In this conversation, Jenn Vehrs shares her journey as a bone marrow donor for her brother with Bonnie Rochman, a writer for Fred Hutch News. Vehrs talks about her experiences growing up with cancer in the family and her professional journey at Fred Hutch. She reflects on the emotional and physical challenges of being a donor at a young age, the honor she felt in helping her brother and the full-circle moment of working at the very institution that played a crucial role in her family's life. Jenn also discusses her parents' battles with cancer and the impact of Fred Hutch on their lives.
/episode/index/show/aedca478-f41a-440a-a05b-50e586446413/id/38076845